Houman joined SV in 2016 as a Venture Partner, was promoted to Partner in 2017 and became a Managing Partner in 2018. He has founded four SV companies, attracting strategic investment into three within 12 months at valuation uplifts. He is currently CEO of Ervaxx and TRexBio and serves on the Dementia Discovery Fund (DDF) Investment Committee.
Prior to joining SVLS Houman co-founded the services company Cardiac Report in 2003, as well as Heart Metabolics in 2008. Heart Metabolics successfully repositioned perhexiline, as a treatment for hypertrophic cardiomyopathy and heart failure. Perhexiline is now in advanced clinical trials and has orphan drug designation. He went on to become Vice President and head of the Clinical Science Group at UCB Pharma before becoming an SV Venture Partner.